Sign inJoin waitlistJoin the waitlist

Eric Wong

Professor of Neurology, Director of Medical Neuro-Oncology · Alpert Medical School

Credentials: · · · ·

History

Memorial Sloan Kettering Cancer Center
1997–1998
Neurology
Barnes-Jewish Hospital
1993–1997
Memorial Sloan Kettering Cancer Center
1990–1993
Rutgers New Jersey Medical School
1989–1990
Rutgers, Robert Wood Johnson Medical School
1985–1989
University of Pennsylvania

Research

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
Journal of Clinical Oncology · 2010 · 3,116 citations
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
Journal of Clinical Oncology · 1999 · First of 8 authors · 760 citations
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
European Journal of Cancer · 2012 · 661 citations

Clark Chen
19 papers · 5 as a fellow
Anand Mahadevan
14 papers
Ekkehard Kasper
10 papers
Ekokobe Fonkem
10 papers · 5 as a fellow
Erik Uhlmann
10 papers
PW
Patrick Wen
10 papers
Sasmit Sarangi
9 papers · 9 as a resident
David Reardon
8 papers
Heinrich Elinzano
8 papers · 8 as a resident
Jan Drappatz
8 papers
Scott Floyd
8 papers
Wafik El-Deiry
8 papers

Grants

The Role of Post Traumatic Stress and Substance P in Melanoma Brain Metastasis
National Cancer Institute · R03
Contact PI · $171.4K · Beth Israel Deaconess Medical Center
2013–2016

Clinical trials

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Principal investigator · Withdrawn · Phase 1, Phase 2
Brown University
2025–2026
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Study director · Completed · Phase 3
NovoCure Ltd.
2009–2017
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Site PI · Recruiting · Phase 1
Orbus Therapeutics, Inc.
2023–2026
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
Site PI · Unknown · Phase 2
Aposense Ltd.
2008–2010